Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact ...

Updated data from the phase 3 ENVISION trial (NCT05243550) point to sustained efficacy of mitomycin for intravesical solution (Zusduri; formerly UGN-102) in patients with recurrent low-grade, ...

The phase 1/2 CaRe PC trial (NCT06056791) assessing INKmune in patients with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary end points, INmune Bio reported ...

Data from the phase 2 EXTEND trial showed that the addition of metastasis-directed therapy to ADT improved measures of systemic disease control.

In this video, Laura Bukavina, MD, MSc, MPH, and Betty Wang, MD, discuss the intersection of circulating tumor DNA (ctDNA) monitoring with emerging therapies for non–muscle invasive bladder cancer ...

Millennial urologists appear to have developed strong opinions on health policy as reflected by their recent social media activity, observes urologist Alan L. Kaplan, MD.

Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

Howard B. Goldman, MD, who was the first to use the device in a clinical setting, shares his initial thoughts on the technology and its role in real-world practice.

One consideration is the setting in which the procedure is performed. The FDA recently expanded the label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, In this interview, ...